Public Health Resources

 

Authors

Karen Deffenbacher, University of Nebraska Medical Center, Omaha
Javeed Iqbal, University of Nebraska Medical Center, Omaha
Warren Sanger, University of Nebraska Medical Center, Omaha
Yulei Shen, University of Nebraska Medical Center, Omaha
Cynthia Lachel, University of Nebraska Medical Center, Omaha
Zhongfeng Liu, University of Nebraska Medical Center, Omaha
Yanyan Liu, University of Nebraska Medical Center, Omaha
Megan Lim, University of Michigan Health System, Ann Arbor
Sherrie Perkins, University of Utah, Salt Lake City
Kai Fu, University of Nebraska Medical Center, Omaha
Lynette Smith, University of Nebraska Medical Center, Omaha
James Lynch, University of Nebraska Medical Center, Omaha
Louis Staudt, National Institutes of Health (NIH), Bethesda, MD
Lisa M. Rimsza, University of Arizona, Tucson
Elaine Jaffe, Center for Cancer Research, NCI, NIH, Bethesda, MDFollow
Andreas Rosenwald, University of Wurzburg, Wurzburg, Germany
German Ott, Robert-Bosch-Hospital, Stuttgart, Germany
Jan Delabie, Norwegian Radium Hospital, University of Oslo, Oslo, Norway
Elias Campo, University of Barcelona, Barcelona, Spain
Randy Gascoyne, British Columbia Cancer Agency, Centre for Lymphoid
Mitchell Cairo, Pathology, and Cell Biology, Columbia University, New York, NY
Dennis Weisenburger, University of Nebraska Medical Center, Omaha
Timothy Greiner, University of Nebraska Medical Center, Omaha
Thomas Gross, Nationwide Children’s Hospital, Columbus, OH
Wing Chan, University of Nebraska Medical Center, Omaha

Date of this Version

4-19-2012

Citation

BLOOD, 19 APRIL 2012 VOLUME 119, NUMBER 16; DOI 10.1182/blood-2011-05-349662

Abstract

Burkitt lymphoma (BL) predominates in pediatric patients, whereas diffuse large B-cell lymphoma (DLBCL) is uncommon. In contrast to adults, BL and DLBCL are treated similarly in children and both entities have superior outcomes in children compared with adults. Gene expression profiling (GEP) and miRNA expression profiling clearly differentiated pediatric DLBCL from BL, forming distinct clusters regardless of patient age. However, pathway analysis of GEP data identified minor differences between corresponding pediatric and adult tumors. Predominance (6:1) of the germinal center B-cell subtype to activated B-cell subtype was found among pediatric DLBCL. Two cases were molecularly classified as primary mediastinal B-cell lymphoma. We observed frequent abnormalities in 8q24 in pediatric DLBCL, including MYC rearrangement in 31% (5 of 16) and gain or amplification in 50% (6 of 12) nonrearranged cases. MYC rearrangement was present in 96% (23 of 24) BL cases. Array-based CGH analysis identified abnormalities that are shared between adult and pediatric DLBCL (+12q15, +19q13, -6q), and abnormalities unique to the pediatric cases (-4p14, -19q13.32, +16p11.2), suggesting distinct pathogenetic mechanisms relative to age. Elucidation of the underlying target genes may provide insight into factors that modulate outcome and could provide potential novel therapeutic targets with less toxicity for pediatric patients with B-cell non-Hodgkin lymphoma.

Included in

Public Health Commons

Share

COinS